Literature DB >> 20375794

Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer.

Hiroyuki Nomura1, Hiroshi Tsuda, Nobuyuki Susumu, Takuma Fujii, Kouji Banno, Fumio Kataoka, Eiichiro Tominaga, Atsushi Suzuki, Tatsuyuki Chiyoda, Daisuke Aoki.   

Abstract

OBJECTIVES: Incidence of lymph node metastasis is relatively high even in early-stage epithelial ovarian cancers (EOC). Lymphadenectomy is important in the surgical treatment of EOC; however, the exact role of lymphadenectomy in the management of EOC remains unclear. In this study, we evaluated lymph node metastasis in stages I and II EOC patients. PATIENTS AND METHODS: Seventy-nine patients with stage I/II EOC underwent initial surgery, and 68 patients received adjuvant platinum and taxane chemotherapy after surgery at Keio University Hospital. The patients were evaluated with respect to age at diagnosis, clinical stage, histology, histological grade, and tumor laterality.
RESULTS: Of the 79 patients, 10 (12.7%) had lymph node metastasis. Of these, 4 (5.1%) had lymph node metastasis in paraaortic lymph node (PAN) only, 1 (1.3%) in pelvic lymph node (PLN) only, and 5 (6.3%) in both PAN and PLN. The incidence of serous-type lymph node metastasis in PAN, PAN + PLN, and total was higher than nonserous type (25% vs 1.5%, P < 0.0001; 25% vs 3.0%, P = 0.001; 50% vs 5.9%, P < 0.0001). However, there was no significant difference between lymph node status and T factor or histological grade. In 78% of patients (7/9), metastases in contralateral lymph nodes were present (contralateral, 2; bilateral, 5). There was no significant difference in progression-free survival between node-positive and node-negative groups (P = 0.47).
CONCLUSIONS: Based on diagnostic value, the result suggests that the role of lymphadenectomy might differ by histological type, as its therapeutic effect might be unclear. A multicenter analysis is essential for confirmation.

Entities:  

Mesh:

Year:  2010        PMID: 20375794     DOI: 10.1111/IGC.0b013e3181cf6271

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  11 in total

1.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

2.  Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.

Authors:  Yinglan Liu; Liqian Yu; Yingwei Wang; Yaling Zhang; Yingchao Wang; Guangmei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-08       Impact factor: 4.553

3.  Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

Authors:  K D Swenerton; J L Santos; C B Gilks; M Köbel; P J Hoskins; F Wong; N D Le
Journal:  Ann Oncol       Date:  2010-08-06       Impact factor: 32.976

4.  A cohort study evaluating paraaortic lymphadenectomy in endometrial cancer.

Authors:  Haiyan Zhang; Zhi Zuo; Ye Wang; Li Wang; Zhiling Zhu
Journal:  Oncol Lett       Date:  2012-09-17       Impact factor: 2.967

5.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

6.  Sentinel node in ovarian cancer: study protocol for a phase 1 study.

Authors:  Marjolein Kleppe; Toon Van Gorp; Brigitte F M Slangen; Arnold J Kruse; Boudewijn Brans; Ivo N A Pooters; Koen K Van de Vijver; Roy F P M Kruitwagen
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279

Review 7.  Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?

Authors:  Masashi Takano; Hiroshi Tsuda; Toru Sugiyama
Journal:  J Exp Clin Cancer Res       Date:  2012-06-01

8.  Role of lymphadenectomy for ovarian cancer.

Authors:  Mikio Mikami
Journal:  J Gynecol Oncol       Date:  2014-10       Impact factor: 4.401

9.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

10.  Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer.

Authors:  Suk-Joon Chang; Robert E Bristow; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.